Latest From Stanford University
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
Scrip spoke with Fred Cohen, who co-founded Vida Ventures with former Kite Pharma CEO Arie Belldegrun, about the venture capital firm's investment focus after raising its second fund in two years.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.